Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants

被引:118
作者
Marinello, Jessica [1 ]
Marchand, Christophe [1 ]
Mott, Bryan T. [2 ]
Bain, Anjali [2 ]
Thomas, Craig J. [2 ]
Pommier, Yves [1 ]
机构
[1] NCI, NIH, Ctr Canc Res, Mol Pharmacol Lab, Bethesda, MD 20892 USA
[2] NHGRI, NIH, NIH Chem Genom Ctr, Bethesda, MD 20892 USA
关键词
D O I
10.1021/bi800791q
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
HIV-1 integrase (IN) is the molecular target of the newly approved anti-AIDS drug raltegravir (MK-0518, Isentress) while elvitegravir (GS-9137, JTK-303) is in clinical trials. The aims of the present study were (1) to investigate and compare the effects of raltegravir and elvitegravir on the three IN-mediated reactions, 3'-processing (3'-P), strand transfer (ST), and disintegration, (2) to determine the biochemical activities of seven IN mutants (T66I, L74M, E92Q, F121Y, Q148K, S153Y, and N155H) previously selected from drug-resistant patients and isolates, and (3) to determine the resistance profile for raltegravir and elvitegravir in those IN mutants. Our findings demonstrate that both raltegravir and elvitegravir are potent IN inhibitors and are highly selective for the ST reaction of IN. Elvitegravir was more potent than raltegravir, but neither drug could block disintegration. All resistance mutations were at least partially impaired for ST. Q148K was also markedly impaired for 3'-P. Both drugs exhibited a parallel resistance profile, although resistance was generally greater for elvitegravir. Q148K and T661 conferred the highest resistance to both drugs while S153Y conferred relatively greater resistance to elvitegravir than raltegravir. Drug resistance could not be overcome by preincubating the drugs with IN, consistent with the binding of raltegravir and elvitegravir at the IN-DNA interface. Finally, we found an inverse correlation between resistance and catalytic activity of the IN Mutants.
引用
收藏
页码:9345 / 9354
页数:10
相关论文
共 50 条
  • [21] Mechanisms of HIV-1 integrase resistance to dolutegravir and potent inhibition of drug-resistant variants
    Li, Min
    Passos, Dario Oliveira
    Shan, Zelin
    Smith, Steven J.
    Sun, Qinfang
    Biswas, Avik
    Choudhuri, Indrani
    Strutzenberg, Timothy S.
    Haldane, Allan
    Deng, Nanjie
    Li, Zhaoyang
    Zhao, Xue Zhi
    Briganti, Lorenzo
    Kvaratskhelia, Mamuka
    Burke Jr, Terrence R. R.
    Levy, Ronald M.
    Hughes, Stephen H.
    Craigie, Robert
    Lyumkis, Dmitry
    SCIENCE ADVANCES, 2023, 9 (29)
  • [22] Elvitegravir: a once-daily inhibitor of HIV-1 integrase
    Wills, Todd
    Vega, Vivian
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (03) : 395 - 401
  • [23] Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir
    Canducci, Filippo
    Marinozzi, Maria Chiara
    Sampaolo, Michela
    Boeri, Enzo
    Spagnuolo, Vincenzo
    Gianotti, Nicola
    Castagna, Antonella
    Paolucci, Stefania
    Baldanti, Fausto
    Lazzarin, Adriano
    Clementi, Massimo
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (03) : 425 - 433
  • [24] Reduced HIV-1 integrase flexibility as a mechanism for raltegravir resistance
    Kovari, L. C.
    Dewdney, T.
    Wang, Y.
    Kovari, I. A.
    ANTIVIRAL THERAPY, 2013, 18 : A116 - A116
  • [25] Drug resistant integrase mutants cause aberrant HIV integrations
    Janani Varadarajan
    Mary Jane McWilliams
    Bryan T. Mott
    Craig J. Thomas
    Steven J. Smith
    Stephen H. Hughes
    Retrovirology, 13
  • [26] Drug resistant integrase mutants cause aberrant HIV integrations
    Varadarajan, Janani
    McWilliams, Mary Jane
    Mott, Bryan T.
    Thomas, Craig J.
    Smith, Steven J.
    Hughes, Stephen H.
    RETROVIROLOGY, 2016, 13
  • [27] Examining structural analogs of elvitegravir as potential inhibitors of HIV-1 integrase
    Kavita Shah
    Saumya Gupta
    Hirdyesh Mishra
    Prashant K. Sharma
    Amit Jayaswal
    Archives of Virology, 2014, 159 : 2069 - 2080
  • [28] Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor
    Lampiris, Harry W.
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2012, 10 (01) : 13 - 20
  • [29] Examining structural analogs of elvitegravir as potential inhibitors of HIV-1 integrase
    Shah, Kavita
    Gupta, Saumya
    Mishra, Hirdyesh
    Sharma, Prashant K.
    Jayaswal, Amit
    ARCHIVES OF VIROLOGY, 2014, 159 (08) : 2069 - 2080
  • [30] A Study on Drug Resistance Mechanism of HIV-1 Integrase Mutants by Molecular Modeling
    Zhang Xiao-Yi
    He Hong-Qiu
    Liu Bin
    Wang Cun-Xin
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2009, 36 (05) : 592 - 600